Calmark plans to launch two additional newborn tests on the same platform to measure the biomarkers LDH and glucose. These biomarkers are relevant to analyze at birth and in the following days to detect hypoxia and low blood sugar.
Development projects for these products have begun but are currently paused to prioritize Calmark's resources to launch and sell Neo-Bilirubin.
